Alprazolam and Simulated Driving Performance: Next Day Effects
Alprazolam and Simulated Driving Performance: Next Day Effects
批准号:
9455117
负责人:
Marion Amanda Coe
金额:
$5.25万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-15 至 2019-08-31
关键词:
AccidentsAcuteAdultAlcoholsAlprazolamAnxietyAnxiety DisordersAreaAutomobile DrivingAutopsyBehavioralBenzodiazepinesBinding SitesBiological AssayBloodCYP3A4 geneClinical ResearchClinical TrialsCommutingControl GroupsDangerousnessDataData AnalysesData CollectionDiazepamDoseDouble-Blind MethodDrug ControlsDrug EvaluationDrug PrescriptionsEnrollmentEvaluationFemaleFundingGuidelinesHourImpairmentInternationalIntoxicationInvestigationLabelLightMarketingMeasurementMeasuresMolecularMonitorMotor VehiclesNational Institute of Drug AbuseOutcome MeasurePanic DisorderPerformancePharmaceutical PreparationsPharmacodynamicsPharmacologyPhase I Clinical TrialsPhysiologicalPlacebo ControlPlacebosPlasmaPoliciesPositioning AttributePrevalencePropertyPsychomotor ImpairmentsPsychomotor PerformancePublic HealthRandomizedRecommendationResearchResearch DesignResearch PrioritySafetySeveritiesSex CharacteristicsSleep disturbancesSleeplessnessStatutes and LawsTestingTherapeuticTimeTraffic accidentsUnited StatesUnited States Food and Drug AdministrationUnited States National Institutes of HealthWomanbasebehavioral outcomecognitive performancedesigndrug clearancedrugged drivingexperimental studygender differencehangoverhealthy volunteerhypnoticimpaired driving performancekillingsmalemenprimary outcomereceptorresearch clinical testingresponsesecondary outcomesedativesexstandard measurevolunteerzolpidem
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
There has been a significant rise in drugged driving, and associated traffic accidents and fatalities, in
the United States over the last decade. While illegal substances account for the majority of drugged–driving
cases, there are a number of prescription medications that can also impair driving ability. Most concerning are
the prescription drugs which may impair driving ability after the presumed duration of therapeutic action. This
phenomenon was highlighted when the FDA mandated relabeling of all hypnotic drugs containing zolpidem
due to the presence of potentially impairing blood concentrations of the drug even after 8 hours; an effect that
had sex-specific in its severity. This effect was exacerbated in females compared to males. Alprazolam shares
many pharmacological properties with zolpidem and converging evidence suggests it may also cause
prolonged psychomotor impairment beyond the proposed therapeutic duration of action. This project proposes
a study enrolling an equal number of male and female healthy volunteers who will participate in six overnight
sessions to evaluate if alprazolam has a negative impact on cognitive or psychomotor performance the
morning after administration compared to positive and negative controls. Performance on a highly
sophisticated driving simulator with high external validity will be tested before and the morning after drug
administration. This randomized, double-blind study will test three therapeutic doses of alprazolam, a
potentially impairing dose of zolpidem, and placebo in a mixed-factorial design—with each subject receiving all
drug conditions. To evaluate if sex influences next-day alprazolam effects, sex will be analyzed as a between-
subjects factor. The proposed experiment will use sensitive behavioral and analytic assessments to yield
quantitative and qualitative data on previously unexplored properties of alprazolam. In light of the prevalence
of drugged driving in the United States, the simulated driving data obtained from this study will have significant
public health and safety implications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金